U.S. FDA Flags Eight Lapses At Biocon’s Insulin Facility In Malaysia

[ad_1] The lapses were related to biologic drug substances, drug product units, quality control laboratories, and delivery device units at the above-mentioned facility, the company said in an exchange filing.…

Biocon’s subsidiary completes integration of Viatris’ biosimilars business; stock rises

[ad_1] Biocon share price: Biocon shares on Friday, December 1, rose over 2 per cent to touch the intra-day high of Rs 245 apiece on BSE, rising for the third…